People with metastatic breast cancer whose tumors had low levels of HER2 protein lived longer after treatment with trastuzumab deruxtecan (Enhertu) than those treated with standard chemotherapy, results of the DESTINY-Breast04 clinical trial show.
New findings from the first large, randomized clinical trial to compare chemotherapy regimens for relapsed or treatment-resistant Ewing sarcoma could help doctors and patients select treatments. In the study, patients who received ifosfamide (Ifex) lived longer than those who received a combination of two other chemotherapy drugs.
The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) was safer and better than standard chemotherapy at shrinking low-grade glioma tumors and keeping them at bay in some children with a genetic mutation known as BRAF V600 in their cancer cells. The treatment also seemed effective for children with high-grade glioma, according to results from a phase 2 trial.
Clinical Trials Information for Patients and Caregivers
Some federal programs may help pay the costs of care in clinical trials for eligible beneficiaries. This page describes those programs and who they can help.
In this phase 3 trial, people who have had one or two small benign polyps removed during a routine screening colonoscopy will be randomly assigned to undergo their next colonoscopy at 5 or 10 years. The findings from the trial will help determine if people who have had up to two small polyps removed during a routine colonoscopy can wait 10 years for another one.
This phase 1 trial will test a combination of six drugs for people with B-cell lymphoma that has either come back or not responded to treatment. Doctors want to see if these drugs are safe and effective against B-cell lymphoma when given together.
This study will examine the immune responses after COVID vaccination in people with cancer aged 6 months to 37 years. Scientists want to see how the immune systems of young people with cancer respond to the COIVD vaccine.
